FDA Approves Weekly Subcutaneous Injection Leqembi Iqlik for Alzheimer’s Treatment

The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for Leqembi Iqlik, a subcutaneous injection designed for the treatment of Alzheimer’s disease. The newly approved formulation allows for weekly administration via injection, offering an alternative to existing treatment methods.

According to reports, this approval aims to improve both convenience and safety in the care of patients with Alzheimer’s. The subcutaneous delivery method is expected to simplify the administration process compared to other forms of treatment, potentially reducing the burden on caregivers and healthcare providers. Further details regarding availability or clinical data supporting this decision have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 2, 2025

Author

Mark Chiang